Cannabinoids trigger a cellular self-destruction program called autophagy in glioblastoma cells, offering a potential treatment approach for this currently incurable brain cancer.
Neuro-oncology researchers, brain cancer patients and families, and scientists studying cannabinoid anticancer mechanisms.
14-month average survival highlights urgent need for new approaches
What the researchers found
Glioblastoma harbors alterations in the endocannabinoid system including changes in CB1 and CB2 receptor expression. Cannabinoid activation of these receptors suppresses proliferation and invasion while activating autophagy pathways. Preclinical studies show cannabinoids reduce GBM growth and enhance chemotherapy responsiveness. Early clinical studies indicate favorable safety profiles and potential survival benefits.
Why it matters
Glioblastoma has an average survival of only 14 months despite treatment. Cannabinoids represent a mechanistically distinct approach that targets cancer cells through autophagy, a pathway not exploited by current therapies.
The numbers in context
Average GBM survival: ~14 months. Cannabinoids suppress proliferation and invasion via CB1R and CB2R. Autophagy induction occurs through ER stress, ceramide synthesis, and AMPK/mTOR pathways.
How the study worked
Comprehensive review synthesizing molecular mechanisms of cannabinoid-induced autophagy and anticancer activity in glioblastoma, covering cell line, animal model, and early clinical data.
What this study cannot tell us
Most evidence is preclinical. Clinical data is limited to early-phase studies. Cannabinoid doses used in preclinical studies may not be achievable in the human brain. Autophagy can paradoxically promote tumor survival under some conditions.
How to read the evidence
Comprehensive mechanistic review with preclinical support, but limited clinical evidence for glioblastoma specifically.
When this study was published
2026 review.
The bigger picture
Autophagy plays dual roles in cancer, sometimes promoting tumor survival and sometimes triggering cell death. Understanding how cannabinoids specifically tip this balance toward cancer cell death in GBM could lead to novel combination therapies.
Questions still open
- Can cannabinoid-induced autophagy be reliably directed toward cancer cell death rather than survival? What combination strategies maximize the anti-GBM effects?
Common questions
Can cannabinoids treat brain cancer?
What is autophagy?
Read the original research
Cannabinoids and the autophagy-related signaling in brain Tumors: From mechanistic insights to therapeutic Frontiers in glioblastoma.
Biochemical pharmacology, 117781
Citation
Rejili, Mokhtar; Farahani, Najma; Alimohammadi, Mina; Hushmandi, Kiavash. (2026). Cannabinoids and the autophagy-related signaling in brain Tumors: From mechanistic insights to therapeutic Frontiers in glioblastoma.. Biochemical pharmacology, 117781. https://doi.org/10.1016/j.bcp.2026.117781
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk